Acoramidis Reduced ATTR-CM Worsening Risk

A new study indicates acoramidis may outperform tafamidis in reducing clinical worsening events in heart patients.

Updated on Sept. 23, 2026 in Heart Disease

Isometric editorial illustration featuring a glass beaker with refined crystalline molecules on a plinth, representing cardiology pharmaceutical research. — A new study indicates that acoramidis reduced the risk of clinical worsening events in patients with transthyretin amyloid cardiomyopathy by 34% compared to tafamidis. AI Illustration. Upload story photo >

Live Poll

Would you discuss switching your prescribed medication with your doctor based on new clinical study data?

Researchers found that patients treated with acoramidis experienced a 34% reduction in clinical worsening compared to those using tafamidis. The study, published in Cardiology and Therapy, utilized U.S. health claims data to evaluate the comparative effectiveness of these TTR stabilizers.

Why it matters

This research provides comparative data on treatments for transthyretin amyloid cardiomyopathy, a progressive and fatal heart condition. Understanding how these therapies perform in real-world settings is crucial for clinicians managing patient outcomes.

A study of 170 acoramidis users and 448 tafamidis users showed a 43% lower risk of diuretic intensification for the acoramidis group. The mean follow-up period across the cohorts was 4.6 months.

The players

Cardiology and Therapy

This peer-reviewed medical journal publishes clinical research and insights related to cardiovascular disease and therapeutic interventions.

The details

The analysis linked Komodo Healthcare Map U.S. claims data with specialty pharmacy information to track 618 total participants. Patients on acoramidis also showed lower rates of initiating alternative therapy at 4.6%, compared to 7.7% for those on tafamidis.

Treatment initiation occurred between December 2024 and April 2025.
The follow-up period for the study concluded in July 2025.
Study results were published on September 23, 2026.

The Big Picture

This study updates the current comparative efficacy data within the ATTR-CM therapeutic landscape. It marks a shift from clinical trial data toward analyzing longitudinal real-world patient outcomes for stabilizers.

Patients and their healthcare providers may use these findings to better understand the comparative performance of TTR stabilizers in daily clinical practice. These results provide new reference points for discussing treatment plans and potential clinical outcomes for those managing heart conditions.

The takeaway

Patients should consult with their cardiologists to discuss how these real-world findings might apply to their specific treatment path. Ongoing research is essential for verifying these early insights into the long-term effectiveness of heart failure therapies.

What happens next

An independent real-world study evaluating acoramidis versus tafamidis using electronic health records is anticipated for release in 2026, with additional data expected at upcoming fall medical meetings.